- Health Canada DPD: NORFLOXACIN (AA PHARMA INC, DIN 02229524) · product monograph (PDF)
- Spain CIMA (Spanish): search for “norfloxacin” (external search; text not reproduced)
Links only. These regulators' terms do not clearly permit reproducing the documents, so no text is shown here. Check the Philippine package insert in the products table.
Contraindications
- Hypersensitivity to quinolones
- History of fluoroquinolone tendinopathy
- Pre-pubertal children
- Pregnancy
Dosing: Adult
- Urinary tract infection: 400 mg twice daily for 7 to 10 days
- Chronic bacterial prostatitis: 400 mg twice daily for 3 to 7 weeks
- Acute bacterial gastroenteritis: 400 mg twice daily for 5 days
- Uncomplicated gonorrhea: 800 mg single dose
Dosing: Altered kidney function
Norfloxacin is a fluoroquinolone excreted largely unchanged in urine (33% to 48% in 24 hours); its half-life rises from 3–4 hours to about 8 hours at creatinine clearance (CrCl) below 30 mL/min/1.73 m2. The New Zealand data sheet halves the daily dose to 400 mg once daily at CrCl below 30 (not on hemodialysis) and has no data for gonorrhea in that group. Fluoroquinolone class warnings apply. It has no current US FDA label.
Kidney function measure: New Zealand data sheet uses creatinine clearance indexed to body surface area (CrCl, mL/min/1.73 m2); threshold 30.
Show full dosing details
- CrCl ≥60 mL/min
- Usual: 400 mg twice daily (urinary tract infection 7 to 10 days; gastroenteritis 5 days; chronic prostatitis 3 to 7 weeks); maximum 800 mg/day (data sheet).
- CrCl 30–59 mL/min
- No dose change at CrCl ≥30 (data sheet).
- CrCl 15–29 mL/min
- CrCl <30 (not on hemodialysis): 400 mg once daily. No dose recommendation for gonorrhea at CrCl ≤30 (data sheet).
- CrCl <15 mL/min (not on dialysis)
- 400 mg once daily; half-life about 8 hours, the same at CrCl <10 and 10–30 (data sheet). Low urinary levels may limit efficacy in urinary infections (our caution).
- Hemodialysis (intermittent)
- The data sheet's reduced dose excludes patients on hemodialysis; no hemodialysis dosing is given. Specialist input; consider another agent.
- Peritoneal dialysis
- No PD dosing in the data sheet.
- CRRT
- No data; oral agent rarely used in CRRT settings.
- Dialyzable? Not stated.
- Monitoring Tendinopathy (higher risk with kidney impairment, transplant, corticosteroids, age); QT risk factors; glucose with sulfonylureas or insulin (dysglycemia, hypoglycemic coma); seizures; hydration (crystalluria). Separate from iron, zinc, antacids, sucralfate by 2 hours (data sheet). Fluoroquinolone restrictions: avoid for mild or self-limiting infections and, unless alternatives are unsuitable, uncomplicated cystitis; special caution over 60 years, in kidney impairment and after transplant (data sheet).
Children (kidney dosing)
- eGFR ≥60
- Contraindicated in pre-pubertal children; not for growing adolescents.
- eGFR 30–59
- Contraindicated in pre-pubertal children; not for growing adolescents.
- eGFR 15–29
- Contraindicated in pre-pubertal children; not for growing adolescents.
- eGFR <15 (not on dialysis)
- Contraindicated in pre-pubertal children; not for growing adolescents.
- Hemodialysis (intermittent)
- Contraindicated in pre-pubertal children; not for growing adolescents.
- Peritoneal dialysis
- Contraindicated in pre-pubertal children; not for growing adolescents.
- CRRT
- Contraindicated in pre-pubertal children; not for growing adolescents.
Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.
renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.
Source: Medsafe (New Zealand) product information (May 19, 2025). This generic has no US FDA label.
Dosing: Pediatric
- Approved ages
- Contraindicated in pre-pubertal children; not for growing adolescents (data sheet).
- Usual dose
- Not applicable.
Kidney dosing in children: see Dosing: Altered kidney function.
renalcarematters.com, reviewedDosage forms
Philippines
- Film-coated tablet: 400 mg
- Tablet: 200 mg, 400 mg
Registered products in the Philippines
6 products registered with the Food and Drug Administration (FDA) Philippines list Norfloxacin as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products6
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
FlamorelNorfloxacin | 400 mg TabletAlu/PVC Blister Pack x 10's Box of 100's | Rx | Flamingo Pharmaceuticals Ltd.India | Hexagon Pharmaceuticals | DR-XY27822 | Sep 9, 2027 | |
FlornoxNorfloxacin | 400 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | Rx | Centurion Remedies Pvt. Ltd.India | TGP Pharma Inc.Importer: Philgen Pharmaceuticals Inc. | DRP-1984 | Jul 9, 2029 | |
ProstacinNorfloxacin | 200 mg TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | Rx | Drugmaker's Laboratories, Inc.Philippines | — | DRP-5718 | Oct 18, 2028 | |
ProstacinNorfloxacin | 400 mg TabletAlu/ Clear PVDC Blister Pack x 10's (Box of 100's) | Rx | Drugmaker’s Laboratories Inc.Philippines | — | DRP-5826 | Oct 6, 2029 | |
Urinox 400Norfloxacin | 400 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | Rx | Centurion Remedies Pvt. Ltd.India | Meedpharma Medical Supplies & Equipment DistributorImporter: Philgen Pharmaceuticals Inc. | DRP-1984-01 | Jul 9, 2029 | |
UritracinNorfloxacin | 400 mg Film-coated TabletAluminum Strip Foil x 10's Box of 100's | Rx | Amherst Laboratories, Inc.Philippines | Trader: RITEMED PHILS., INC. | DR-XY36232 | Jul 13, 2029 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
Drug interactions
| Drug or class | Severity | Effect | What to do |
|---|---|---|---|
| Iron, zinc, multivitamins, magnesium or aluminum antacids, sucralfate, didanosine | Adjust or monitor | Lower absorption. | Do not take within 2 hours of norfloxacin. |
| Theophylline, CYP1A2 substrates (clozapine, tizanidine), caffeine | Adjust or monitor | Higher levels. | Monitor levels; adjust. |
| Warfarin | Adjust or monitor | INR rise. | Monitor prothrombin time. |
| Cyclosporine | Adjust or monitor | Higher cyclosporine levels. | Monitor levels. |
| Sulfonylureas, insulin | Adjust or monitor | Dysglycemia, hypoglycemic coma. | Monitor glucose. |
| Corticosteroids | Adjust or monitor | Tendon rupture. | Avoid combination where possible. |
| NSAIDs | Adjust or monitor | Seizure risk. | Use with caution. |
| Dairy, enteral nutrition | Minor | Lower absorption. | Take 1 hour before or 2 hours after. |
Severity scale (renalcarematters.com): Avoid: do not combine; Adjust or monitor: change the dose or monitor closely; Minor: usually no action.
renalcarematters.com, reviewedAdverse reactions
Serious
- Tendinitis and tendon rupture
- QT prolongation, torsades de pointes
- Seizures, peripheral neuropathy, psychiatric reactions
- Aortic aneurysm and dissection
- Hypoglycemic coma
- Myasthenia gravis exacerbation
- Clostridioides difficile colitis; DRESS; anaphylaxis
Monitoring parameters
- Tendinopathy (higher risk with kidney impairment, transplant, corticosteroids, age); QT risk factors; glucose with sulfonylureas or insulin (dysglycemia, hypoglycemic coma); seizures; hydration (crystalluria). Separate from iron, zinc, antacids, sucralfate by 2 hours (data sheet). Fluoroquinolone restrictions: avoid for mild or self-limiting infections and, unless alternatives are unsuitable, uncomplicated cystitis; special caution over 60 years, in kidney impairment and after transplant (data sheet). Kidney
- Fluoroquinolone restrictions: not for mild or self-limiting infections; caution over 60 years, in kidney impairment and after transplant
- Tendon symptoms
- Glucose in diabetes
- ECG if QT risk factors
Pharmacokinetics
Key PK parameters
| Bioavailability | At least 30% to 40% absorbed |
|---|---|
| Time to peak | About 1 hour |
| Half-life | 3 to 4 hours |
| Half-life in kidney failure (ESKD) kidney | About 8 hours at CrCl <30 (no difference between <10 and 10–30) |
| Protein binding | 10% to 15% |
| Renal excretion kidney | 33% to 48% unchanged in urine in 24 hours; about 30% in feces; renal clearance about 275 mL/min |
| Dialyzability kidney | Not stated |
Formulary and pricing (Philippines)
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- Medsafe (New Zealand Medicines and Medical Devices Safety Authority). Arrow-Norfloxacin 400 mg tablets data sheet [Medsafe (New Zealand) product information, May 19, 2025; no US FDA label]. https://www.medsafe.govt.nz/profs/datasheet/a/ArrowNorfloxacintab.pdf
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- Teva Pharma (New Zealand) Limited. (2025). Arrow-Norfloxacin 400 mg film-coated tablets [New Zealand data sheet, version 2.0; revised May 19, 2025]. Medsafe, New Zealand Medicines and Medical Devices Safety Authority. https://www.medsafe.govt.nz/profs/datasheet/a/ArrowNorfloxacintab.pdf
renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026.
Last updated: .